148 related articles for article (PubMed ID: 18782815)
1. A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours.
Stronge RL; Turner GB; Johnston BT; McCance DR; McGinty A; Patterson CC; Ardill JE
Ann Clin Biochem; 2008 Nov; 45(Pt 6):560-6. PubMed ID: 18782815
[TBL] [Abstract][Full Text] [Related]
2. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
[TBL] [Abstract][Full Text] [Related]
3. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
Rustagi S; Warner RR; Divino CM
J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
[TBL] [Abstract][Full Text] [Related]
4. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
[TBL] [Abstract][Full Text] [Related]
5. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
[TBL] [Abstract][Full Text] [Related]
6. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.
Desai DC; O'Dorisio TM; Schirmer WJ; Jung SS; Khabiri H; Villanueva V; Martin EW
Regul Pept; 2001 Jan; 96(3):113-7. PubMed ID: 11111016
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.
Garbrecht N; Anlauf M; Schmitt A; Henopp T; Sipos B; Raffel A; Eisenberger CF; Knoefel WT; Pavel M; Fottner C; Musholt TJ; Rinke A; Arnold R; Berndt U; Plöckinger U; Wiedenmann B; Moch H; Heitz PU; Komminoth P; Perren A; Klöppel G
Endocr Relat Cancer; 2008 Mar; 15(1):229-41. PubMed ID: 18310290
[TBL] [Abstract][Full Text] [Related]
8. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Grozinsky-Glasberg S; Grossman AB; Korbonits M
Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.
Strosberg D; Schneider EB; Onesti J; Saunders N; Konda B; Shah M; Dillhoff M; Schmidt CR; Shirley LA
Ann Surg Oncol; 2018 Nov; 25(12):3613-3620. PubMed ID: 30182331
[TBL] [Abstract][Full Text] [Related]
10. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
11. [Neurendocrine tumours of the appendix, colon and rectum: current surgical aspects].
Rosato L; De Tomaa G; Mondini G; Bertone P; Fornari F; Orlassino R
Chir Ital; 2007; 59(4):445-52. PubMed ID: 17966763
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].
Sperlongano P; De Falco M; Pisaniello D; Parmeggiani D; Parmeggiani U
Minerva Endocrinol; 2001 Dec; 26(4):293-5. PubMed ID: 11782719
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin analogs for the treatment of neuroendocrine tumors.
Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
[TBL] [Abstract][Full Text] [Related]
14. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
Uomo G; Germano D; Rabitti PG
Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cells as prognostic markers in neuroendocrine tumors.
Khan MS; Kirkwood A; Tsigani T; Garcia-Hernandez J; Hartley JA; Caplin ME; Meyer T
J Clin Oncol; 2013 Jan; 31(3):365-72. PubMed ID: 23248251
[TBL] [Abstract][Full Text] [Related]
16. Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients.
Srirajaskanthan R; Toumpanakis C; Karpathakis A; Marelli L; Quigley AM; Dusmet M; Meyer T; Caplin ME
Lung Cancer; 2009 Jul; 65(1):68-73. PubMed ID: 19070398
[TBL] [Abstract][Full Text] [Related]
17. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
[TBL] [Abstract][Full Text] [Related]
20. [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
Bodelier AG; Haak HR
Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1868-72. PubMed ID: 16970007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
